We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+7.98%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$6.25B
AUM Growth
-$1.7B
Cap. Flow
-$174M
Cap. Flow %
-2.78%
Top 10 Hldgs %
54.24%
Holding
331
New
77
Increased
88
Reduced
65
Closed
73

Top Buys

Rank Stock Value
1
FIVN icon
FIVE9
FIVN
+$41.6M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$39M
3
DPZ icon
Domino's
DPZ
+$33.2M
4
INCY icon
Incyte
INCY
+$27.6M
5
HUM icon
Humana
HUM
+$26.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$109M
2
EXAS
Exact Sciences
EXAS
+$59.2M
3
SNY icon
Sanofi
SNY
+$49.7M
4
KDP icon
Keurig Dr Pepper
KDP
+$49.6M
5
GSK icon
GSK
GSK
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 41.61%
2 Miscellaneous 38.9%
3 Consumer Discretionary 7.13%
4 Consumer Staples 5.35%
5 Technology 5.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$80.4B
$1.15B 18.37%
5,200,000
-4,400,000
-46% -$942M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$811B
$1.15B 18.35%
2,000,000
-1,900,000
-49% -$1.05B
PTCT icon
3
PTC Therapeutics
PTCT
$5.77B
$268M 4.29%
7,234,898
+272,671
+4% +$9.13M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.48B
$159M 2.54%
5,096,000
-176,000
-3% -$5.49M
INCY icon
5
Incyte
INCY
$25.4B
$145M 2.32%
2,196,105
+432,105
+24% +$27.6M
CYTK icon
6
CALL
Cytokinetics
CYTK
$10.6B
$116M 1.86%
2,200,000
+1,200,000
+120% +$66.9M
TVTX icon
7
Travere Therapeutics
TVTX
$6.14B
$107M 1.71%
7,648,000
+148,000
+2% +$1.54M
IMVT icon
8
Immunovant
IMVT
$8.25B
$101M 1.62%
3,548,000
+151,091
+4% +$4.46M
CYTK icon
9
Cytokinetics
CYTK
$10.6B
$100M 1.6%
1,896,575
-169,416
-8% -$9.44M
AGIO icon
10
Agios Pharmaceuticals
AGIO
$2.01B
$98.1M 1.57%
2,207,070
+127,919
+6% +$5.81M
GRFS
11
Grifois
GRFS
$5.3B
$84.7M 1.35%
9,536,000
+1,644,000
+21% +$13.4M
ARGX icon
12
argenx
ARGX
$63.2B
$82.4M 1.32%
152,000
-48,000
-24% -$24.3M
NARI
13
DELISTED
Inari Medical, Inc. Common Stock
NARI
$75.1M 1.2%
1,822,000
+812,748
+81% +$39M
BUD icon
14
AB InBev
BUD
$157B
$72.4M 1.16%
1,092,000
+253,000
+30% +$15.6M
XRAY icon
15
Dentsply Sirona
XRAY
$2.2B
$71.6M 1.15%
2,646,772
+348,772
+15% +$8.91M
NVO
16
Novo Nordisk
NVO
$201B
$67.3M 1.08%
565,000
+21,000
+4% +$2.8M
AUPH icon
17
Aurinia Pharmaceuticals
AUPH
$2.17B
$60.1M 0.96%
8,200,000
-2,936,000
-26% -$18.2M
BHVN icon
18
Biohaven
BHVN
$2.28B
$59.9M 0.96%
1,199,495
-197,473
-14% -$7.68M
OFIX icon
19
Orthofix Medical
OFIX
$373M
$58.9M 0.94%
3,768,000
+18,000
+0.5% +$288K
MDT icon
20
Medtronic
MDT
$118B
$57.3M 0.92%
635,928
-188,583
-23% -$15.9M
HUM icon
21
Humana
HUM
$48.8B
$56.4M 0.9%
178,085
+74,391
+72% +$26.5M
FIVN icon
22
FIVE9
FIVN
$2.36B
$53.9M 0.86%
1,876,000
+1,153,418
+160% +$41.6M
KURA icon
23
Kura Oncology
KURA
$1.14B
$51.9M 0.83%
2,658,000
+308,000
+13% +$6.24M
SMPL icon
24
Simply Good Foods
SMPL
$955M
$49.1M 0.78%
1,411,120
+453,957
+47% +$15.4M
SPB icon
25
Spectrum Brands
SPB
$2.04B
$47.1M 0.75%
495,000
+55,623
+13% +$4.92M
1
2 3 4 5

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Armistice Capital held 331 positions worth $6.25B, down 21% from $7.95B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Armistice Capital's Q3 2024 filing shows 77 new, 88 increased, 65 reduced and 73 closed positions. Its largest new stake was Paramount Global Class B: 2,000,000 shares worth $21.2M. The largest sale was Neurocrine Biosciences, an estimated $109M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 33% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Armistice Capital's largest Q3 2024 buy was Paramount Global Class B: 2,000,000 shares worth $21.2M.
  • Armistice Capital added most to FIVE9 in Q3 2024, an estimated $41.6M increase.
  • Armistice Capital's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $109M.
  • Armistice Capital fully exited Exact Sciences in Q3 2024, selling an estimated $59.2M.
  • Armistice Capital's ten largest holdings make up 54% of its $6.25B portfolio in Q3 2024.
  • Armistice Capital opened 77 new positions and closed 73 in Q3 2024.
  • Armistice Capital's portfolio value fell 21% quarter-over-quarter to $6.25B.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.